EPIX

NASDAQ

ESSA Pharma Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations

News25/Ratings5

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.

News · 26 weeks40%

2025-10-262026-04-19

Mix090d

No activity.

Latest news

25 items

158dSEC
SEC Form EFFECT filed by ESSA Pharma Inc.
EFFECT - ESSA Pharma Inc. (0001633932) (Filer)
160dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by ESSA Pharma Inc.
SCHEDULE 13G/A - ESSA Pharma Inc. (0001633932) (Subject)
160dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by ESSA Pharma Inc.
SCHEDULE 13G/A - ESSA Pharma Inc. (0001633932) (Subject)
177dSEC
SEC Form 15-12G filed by ESSA Pharma Inc.
15-12G - ESSA Pharma Inc. (0001633932) (Filer)
190dINSIDER
President and CEO Parkinson David Ross returned 65,675 shares to the company, closing all direct ownership in the company (SEC Form 4)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
190dINSIDER
Chief Financial Officer Wood David S. returned 33,343 shares to the company, closing all direct ownership in the company (SEC Form 4)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
190dINSIDER
Director Berger Franklin M returned 784,404 shares to the company, closing all direct ownership in the company (SEC Form 4)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
190dINSIDER
Director Glickman Richard M returned 43,240 shares to the company, closing all direct ownership in the company (SEC Form 4)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
190dINSIDER
Director Requadt Scott returned 30,002 shares to the company, closing all direct ownership in the company (SEC Form 4)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
190dINSIDER
Director Martin John Alexander returned 14,299 shares to the company, closing all direct ownership in the company (SEC Form 4)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
190dINSIDER
Director Thorell Marella returned 2,881 shares to the company, closing all direct ownership in the company (SEC Form 4)
4 - ESSA Pharma Inc. (0001633932) (Issuer)
190dSEC
SEC Form POS AM filed by ESSA Pharma Inc.
POS AM - ESSA Pharma Inc. (0001633932) (Filer)
190dSEC
SEC Form S-8 POS filed by ESSA Pharma Inc.
S-8 POS - ESSA Pharma Inc. (0001633932) (Filer)
190dSEC
SEC Form S-8 POS filed by ESSA Pharma Inc.
S-8 POS - ESSA Pharma Inc. (0001633932) (Filer)
190dSEC
SEC Form S-8 POS filed by ESSA Pharma Inc.
S-8 POS - ESSA Pharma Inc. (0001633932) (Filer)
190dSEC
SEC Form S-8 POS filed by ESSA Pharma Inc.
S-8 POS - ESSA Pharma Inc. (0001633932) (Filer)
190dSEC
SEC Form S-8 POS filed by ESSA Pharma Inc.
S-8 POS - ESSA Pharma Inc. (0001633932) (Filer)
191dINSIDER
SEC Form 4 filed by Large owner Bvf Partners L P/Il
4 - ESSA Pharma Inc. (0001633932) (Issuer)
191dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by ESSA Pharma Inc.
SCHEDULE 13D/A - ESSA Pharma Inc. (0001633932) (Subject)
196dSEC
SEC Form 25-NSE filed by ESSA Pharma Inc.
25-NSE - ESSA Pharma Inc. (0001633932) (Subject)
196dPR
ESSA Announces Completion of Arrangement with XenoTherapeutics
SOUTH SAN FRANCISCO, Calif., USA and VANCOUVER, BC, Canada, Oct. 9, 2025 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ:EPIX) ("ESSA" or the "Company") today announced the completion of XenoTherapeutics' ("Xeno") previously announced acquisition of ESSA (the "Acquisition"). Xeno Acquisition Corp., a wholly owned subsidiary of Xeno, has acquired all of the outstanding common shares of ESSA (the "Common Shares") for approximately US$0.1242 per Common Share, plus one contingent value right ("CVR") per Common Share, which CVR represents the right to receive up to approximately US$0.14 per CVR and payable within specified periods following the close of the Acquisition. The potential CVR payment of US$0
196dSEC
ESSA Pharma Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Other Events, Financial Statements and Exhibits
8-K - ESSA Pharma Inc. (0001633932) (Filer)
198dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by ESSA Pharma Inc.
SCHEDULE 13G/A - ESSA Pharma Inc. (0001633932) (Subject)
199dSEC
ESSA Pharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
8-K - ESSA Pharma Inc. (0001633932) (Filer)
199dPR
ESSA Securityholders Approve Acquisition by XenoTherapeutics
SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, Oct. 6, 2025 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ:EPIX) ("ESSA" or the "Company") is pleased to announce that its Securityholders (as defined below) have approved the acquisition of all of the issued and outstanding common shares of the Company (the "Common Shares" and the holders of such Common Shares, the "Shareholders") by XenoTherapeutics Inc. ("Xeno"), a non-profit biotechnology company, by way of a statutory plan of arrangement (the "Transaction" or the "Arrangement") at the special meeting of Securityholders held today (the "Meeting"). The special resolution approving the Arrangement was approved by: (i) 99.83% of the votes cast by S